PROVIDING TIMELY PATIENT-CENTERED MOLECULAR DIAGNOSTIC TESTING FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA: A QUALITY IMPROVEMENT STUDY

Introduction: At many centers, molecular diagnostic (MD) testing for Acute Myeloid Leukemia (AML) struggles to meet turn-around-time (TAT) required for therapeutic decision-making. At our tertiary referral centre, TAT for MD (karyotyping and next-generation sequencing [NGS]) exceeded 4 weeks, result...

Full description

Bibliographic Details
Main Authors: A. Qureshi, J. Ho, L. Schenkel, B. Chin-Yee, U. Deotare, A. Meybodi, L. Saini, B. Sadikovic, I. Chin-Yee
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Leukemia Research Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048924000128